Related Read: 14 Peptides Are About to Become Legal Again What This Means for Your Health What the science says about peptide stacking as a category 1) Combination trials are the exception, not the rule For many popular peptides, we have: mechanistic arguments small studies (sometimes in narrow contexts) preclinical work We rarely have: well-powered, long-term human trials on the combination hard outcomes (function, cardiometabolic endpoints, durability, safety) 2) Stacking amplifies the two biggest risks in this space Quality risk (variable purity, contamination, labeling issues) Physiology risk (more pathways affected, more unintended effects) 3) The GH/IGF-1 axis is where stacking gets most clinically delicate CJC-1295 has human data showing it raises GH/IGF-1
GLOBAL GLUTATHIONE MARKET SIZE, BY SKIN WHITENING, 2018-2032 (USD MILLION) TABLE 21
The Staging of Lung Cancer
Are microbiome changes from artificial sweeteners substantial enough to cause obesity and diabetes
Mol Immunol 132:227235 Zhang Z, Chen W-Q, Zhang S-Q, Bai J-X, Lau C-L, Sze SC-W, Yung KK-L, Ko JK-S (2022) The human cathelicidin peptide LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming of the tumor immune microenvironment
